Methylation of serum insulin-like growth factor-binding protein 7 promoter in hepatitis B virus-associated hepatocellular carcinoma

Genes Chromosomes and Cancer

Volumn 53, Issue 1, 2014, Pages 90-97

  Li, Feng ^a,b   Fan, Yu Chen ^a,b   Gao, Shuai ^a   Sun, Feng Kai ^a   Yang, Yang ^a   Wang, Kai ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 7; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA METHYLATION; FEMALE; GENE; GENE FREQUENCY; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; IGFBP7 GENE; LIVER CELL CARCINOMA; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

HEPATITIS B VIRUS;

ADULT; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DNA METHYLATION; FEMALE; HEPATITIS B; HEPATITIS B, CHRONIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84887628654     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22120     Document Type: Article

References (34)

1. Bird A. 1992. The essentials of DNA methylation. Cell 70:5-8.
2. Bruix J, Sherman M. 2005. Management of hepatocellular carcinoma. Hepatology 42:1208-1236.
3. Bruix J, Sherman M. 2011. Management of hepatocellular carcinoma: An update. Hepatology 53:1020-1022.
4. Chan KC, Lai PB, Mok TS, Chan HL, Ding C, Yeung SW, Lo YM. 2008. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin Chem 54:1528-1536.
5. Chen Y, Pacyna-Gengelbach M, Ye F, Knösel T, Lund P, Deutschmann N, Schlüns K, Kotb WF, Sers C, Yasumoto H, Usui T, Petersen I. 2007. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has potential tumoursuppressive activity in human lung cancer. J Pathol 211:431-438.
6. Degeorges A, Wang F, Frierson HF, Jr., Seth A, Sikes RA. 2000. Distribution of IGFBP-rP1 in normal human tissues. J Histochem Cytochem 48:747-754.
7. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA, Jr. 2008. Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985-990.
8. Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P. 2004. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 10:6189-6193.
9. Egger G, Liang G, Aparicio A, Jones PA. 2004. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457-463.
10. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. 2008. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134:1752-1763.
11. Esteller M. 2008. Epigenetics in cancer. N Engl J Med 358:1148-1159.
12. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. 1999. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59:67-70.
13. Herman JG, Baylin SB. 2003. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054.
14. Huang ZH, Hu Y, Hua D, Wu YY, Song MX, Cheng ZH. 2011. Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma. Exp Mol Pathol 91:702-707.
15. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin 61:69-90.
16. Jones PA, Laird PW. 1999. Cancer epigenetics comes of age. Nat Genet 21:163-167.
17. Jones PA, Baylin SB. 2007. The epigenomics of cancer. Cell 128:683-692.
18. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. 1977. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37:646-650.
19. Lin J, Lai M, Huang Q, Ma Y, Cui J, Ruan W. 2007. Methylation patterns of IGFBP7 in colon cancer cell lines are associated with levels of gene expression. J Pathol 212:83-90.
20. Lok AS, McMahon BJ. 2009. Chronic hepatitis B: Update 2009. Hepatology 50:661-662.
21. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL. 2010. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 138:493-502.
22. Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A, Malaguarnera M. 2010. Serum markers of hepatocellular carcinoma. Dig Dis Sci 55:2744-2755.
23. Maluccio M, Covey A. 2012. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 62:394-399.
24. Sato Y, Chen Z, Miyazaki K. 2007. Strong suppression of tumor growth by insulin-like growth factor-binding protein-related protein 1/tumor-derived cell adhesion factor/mac25. Cancer Sci 98:1055-1063.
25. Shukla S, Mirza S, Sharma G, Parshad R, Gupta SD, Ralhan R. 2006. Detection of RASSF1A and RARβ hypermethylation in serum DNA from breast cancer patients. Epigenetics 1:88-93.
26. Smith P, Nicholson LJ, Syed N, Payne A, Hiller L, Garrone O, Occelli M, Gasco M, Crook T. 2007. Epigenetic inactivation implies independent functions for insulin-like growth factor binding protein (IGFBP)-related protein 1 and the related IGFBPL1 in inhibiting breast cancer phenotypes. Clin Cancer Res 13:4061-4068.
27. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. 1989. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 46:318-322.
28. Sullivan L, Murphy TM, Barrett C, Loftus B, Thornhill J, Lawler M, Hollywood D, Lynch T, Perry AS. 2012. IGFBP7 promoter methylation and gene expression analysis in prostate cancer. J Urol 188:1354-1360.
29. Tomimaru Y, Eguchi H, Wada H, Kobayashi S, Marubashi S, Tanemura M, Umeshita K, Kim T, Wakasa K, Doki Y, Mori M, Nagano H. 2012. IGFBP7 downregulation is associated with tumor progression and clinical outcome in hepatocellular carcinoma. Int J Cancer 130:319-327.
30. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notariis S, Roda E, Bernardi M. 2001. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: Influence of HBsAg and anti-HCV status. J Hepatol 34:570-575.
31. Vizioli MG, Sensi M, Miranda C, Cleris L, Formelli F, Anania MC, Pierotti MA, Greco A. 2010. IGFBP7: An oncosuppressor gene in thyroid carcinogenesis. Oncogene 29:3835-3844.
32. Wong IH, Lo YM, Zhang J, Liew CT, Ng MH, Wong N, Lai PB, Lau WY, Hjelm NM, Johnson PJ. 1999. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 59:71-73.
33. Wong IH, Lo YM, Yeo W, Lau WY, Johnson PJ. 2000. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res 6:3516-3521.
34. Zhang YJ, Wu HC, Shen J, Ahsan H, Tsai WY, Yang HI, Wang LY, Chen SY, Chen CJ, Santella RM. 2007. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res 13:2378-2384.